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Abstract 
Signals induced by mechanical loading and C-type natriuretic peptide (CNP) 
represent chondroprotective routes that may potentially prevent osteoarthritis (OA).  
We examined whether CNP will reduce hyaluronan production and export via 
members of the multidrug resistance protein (MRP) and diminish pro-inflammatory 
effects in human chondrocytes. The presence of interleukin-1β (IL-1β) increased HA 
production and export via MRP5 that was reduced with CNP and/or loading. 
Treatment with IL-1β conditioned medium increased production of catabolic 
mediators and the response was reduced with the hyaluronan inhibitor, Pep-1. The 
induction of pro-inflammatory cytokines by the conditioned medium was reduced by 
CNP and/or Pep-1, αCD44 or αTLR4 in a cytokine-dependent manner, suggesting 
that the CNP pathway is protective and should be exploited further.  
  
Keywords: C-type natriuretic peptide, interleukin-1β, chondrocyte, mechanical 
loading, osteoarthritis.  
 
Introduction  
The importance of the C-type natriuretic peptide (CNP) pathway is evident in 
regulating joint homeostasis [1-3]. In chondrocytes, CNP binds to natriuretic peptide 
receptor (Npr) 2 leading to synthesis of cyclic guanosine-3’,5’-monophosphate 
(cGMP) and homeostasis. CNP also binds to Npr3 that degrades the peptide and 
reduces beneficial signalling via Npr2 [4]. CNP treatment of cell lines, monolayers or 
pellet culture increased chondrocyte differentiation, proliferation and matrix 
synthesis, mediated by Npr2/cGMP [5-9]. In the chondrocyte/agarose model, the 
protective effects of CNP were enhanced by mechanical loading [10-11]. Taken 
together, the evidence indicates that the effects of CNP are mediated via Npr2 and 
its antagonism inhibits the protective actions of CNP in cartilage.  
We previously reported that CNP or mechanical loading upregulates 
intracellular and extracellular levels of cGMP [11], but the way in which it is exported 
in chondrocytes is unclear. In fibroblasts, the multidrug resistance protein 5 (MRP5) 
was reported to export both HA and cGMP [12-13]. However, agents designed to 
inhibit HA export by increasing cGMP levels prevent proteoglycan and collagen loss 
in OA affected cartilage explants [14-15]. Since we reported that cGMP levels were 
also influenced by CNP, IL-1and mechanical loading [11], the action of cGMP on 
preventing HA export could potentially be chondroprotective and might reduce the 
downstream actions of HA signalling and its breakdown. However, HA fragmentation 
is influenced by mechanical loading or the presence of hyaluronidases or free 
radicals typically found in the OA joint [16-18]. It was reported that the HA binding 
receptors, CD44 or Toll-Like Receptor 4 (TLR4) promotes inflammatory effects 
induced by hyaluronidase treatment [19-24]. We hypothesised that induction of 
cGMP by CNP and mechanical loading will reduce HA production and export that 
prevents the catabolic effects induced by HA fragmentation. These impacts may alter 
both quantity and size distribution of HA, and play an important role in balancing the 
protective and inflammatory effects mediated by CNP and HA fragmentation. 
 
Materials and Methods  
Cell isolation and 3D agarose culture: Human cartilage was obtained from sixteen 
patients with ethical approval (East London and The City Research Ethics 
Committee) and informed patient consent, undergoing total knee arthroplasty at the 
Royal London Hospital, Barts Health NHS Trust, London, UK. Cartilage was 
removed from the femoral condyles and tibial plateaux with experiments repeated 
with cells from 3-4 donors. Chondrocytes were isolated from tissue explants and 
resuspended in DMEM + 20% FCS at a cell concentration of 8 × 106 cells/ml using 
well-established protocols [10-11]. The cell suspension was added to an equal 
volume of molten 6% (wt/vol) agarose type VII in Earle Balanced Salt Solutions 
(EBSS) to yield a final cell concentration of 4 × 106 cells/ml in 3% (wt/vol) agarose 
(Sigma-Aldrich, Poole, UK). The chondrocyte/agarose suspension was allowed to 
gel at 4C for 20 min in a sterile stainless steel mould, containing holes 5 mm in 
diameter and 5 mm in height. Constructs were equilibrated in culture in DMEM + 
10% FCS at 37C in 5% CO2 for 24 hours (Sigma-Aldrich, Poole, UK). 
 
Effect of agents that interfere with the MRP/Npr pathway: The effect of IL-1β and 
CNP on HA production was investigated in free-swelling culture. Equilibrated 
constructs were cultured with 0 or 10ng/mL IL-1 and/or 100nM CNP or 1M MK571 
(inhibits MRP5), 0.5µM cyclic gly-24-ser (P19, selective Npr2 antagonist, Gentaur 
Molecular Products, Whetsone, UK) or 1µM c-Atrial Natriuretic Factor (cANF4-23, 
selective Npr3 agonist, Bachem AG, Bubendorf, Switzerland) [11]. In separate 
experiments, constructs were subjected to 15% dynamic compression at 1Hz 
frequency (10min every 6 hours) using well-established protocols [10-11] for 48 
hours. Media was supplemented with 0 or 10ng/ml IL-1β and/or 100 nM CNP and/or 
0.5µM P19 and/or 1µM cANF4-23. Controls were unstrained in the bioreactor and 
cultured for the same time period.  
 
The effect of conditioned media and agents that influence the HA pathway: The 
role of HA and its fragments on promoting inflammatory effects was investigated with 
conditioned medium, and/or specific pharmacological agents that inhibit downstream 
effects on two HA receptors, CD44 and TLR4. Constructs were cultured with 0 or 10 
ng/ml IL-1 and/or 100nM CNP for 48 hours. 300µL of the supernatant was used as 
conditioned medium to treat patient-matched constructs for the following conditions: 
- Untreated conditioned media (UTCM) 
- CNP conditioned media (CNPCM)  
- IL-1β conditioned media (IL-1βCM) 
- IL-1β + CNP conditioned media (IL-1β + CNPCM) 
 
Conditioned medium was supplemented with HA binding peptide Pep-1 (30 µM, 
AnaSpec), which blocks binding of small HA fragments and prevents downstream 
signalling [25-26]. For analysis of the HA binding mechanism, conditioned media was 
treated with specific antibodies that blocked HA binding to CD44 (clone Bu52, 
AbDSerotec, Kidlington, UK) or TLR4 (anti-CD284 clone HTA125, AbDSerotec, 
Kidlington, UK). Both antibodies were used at 2µg/mL and were shows to block 
activity [26-27]. Constructs were cultured with conditioned media with P19 and cANF 
for a further 48 hours. 
 
Gene expression analysis: Total RNA was isolated with the QIAquick Spin gel 
extraction and RNeasy kits (Qiagen,West Sussex, UK), reverse transcribed (200 ng) 
with Enhanced Avian RT First Strand cDNA synthesis kit (Sigma Genosys, 
Cambridge, UK) and real-time PCR reactions performed on the Mx3000P 
quantitative PCR instrument (Stratagene, Amsterdam, The Netherlands) using well 
established protocols [28].  The following specific primer sequences were used: 
MRP2 sense: 5’CGTTGTTGCCATCTTAGG-3’, antisense: 5’-
CAAACATCATTGCTGGGTAA-3’; MRP4 sense: 5’-GCAGTTCTAATCATTCTC-3’, 
antisense: 5’-AAATCTCCTTCTTTCTCA-3’; MRP5 sense: 5’-
CTTGTCCTGGAAGATGTT-3’, antisense: 5’-GAAGATGTCATTCACTAGC-3’ (Sigma 
Genosys, Cambridge, UK).  The real-time PCR efficiencies (E) of amplification for 
each target were defined according to the relation, E = 10[-1/slope], and revealed 
efficiency values ranging from 1.94 to 2.03 for optimal primer pairs concentrations 
(0.3 M) derived from standard curves (n = 3). The Ct values for GAPDH remained 
stable, with no changes detected under all culture conditions, suggesting its 
suitability as a reference gene. Relative quantification of MRPs were normalized to 
the target ∆Ct and reference GAPDH ∆Ct, and to the calibrator sample by a 
comparative Ct approach, as described [28].  
 
Biochemical analysis: NO, PGE2 and HA production were determined in 
supernatant by Griess, EIA (GE Healthcare, Buckinghamshire, UK) or ELISA (R&D 
Systems, UK), using well established methods [10-11]. Total MMP activity was 
measured with fluorogenic MMP substrate  at excitation and emission values of 340 
and 440nm, respectively (Enzo Life Sciences, Exeter, UK). GAG synthesis was 
measured by DMMB assay and normalised to DNA values using Hoescht 33258.  
Cytokines were measured with Human Th1/Th2 10-plex tissue culture MSD plates 
according to manufacturer’s instructions (Meso Scale Discovery, Rockville, USA).  
 
Statistics: Statistical analysis was performed by a two-way analysis of variance 
(ANOVA) and the multiple post hoc Bonferroni-corrected t-tests to compare 
differences between the various treatment groups as indicated in the figure legend. 
For gene-expression data, ratio values were log transformed before analysis by a 
two-way ANOVA and a post hoc Bonferroni-corrected t test. In all cases, a level of 
5% was considered statistically significant (P < 0.05). 
 
Results 
 
MRP transporters are regulated by IL-1β and CNP: MRP5 gene expression was 
reduced with CNP when compared to untreated controls (p<0.05, Fig. 1A). IL-1β 
enhanced MRP5 (p<0.001) but was reduced with CNP (p<0.01).  In the absence of 
IL-1β, the pattern of MRPs2 and MRP4 gene expression was similar to MRP5, with a 
significant downregulation with CNP when compared to untreated controls (both 
p<0.001). In the presence of IL-1β, MRP2 and MRP4 expression was increased 
(both p<0.05) but reduced with CNP (Fig. 1B and C).  
 
IL-1β increased HA and the response was inhibited by CNP and/or dynamic 
compression: MRP5 mediates export of cGMP, but is also a HA exporter, an 
activity inhibited by cGMP. We therefore considered whether the production of cGMP 
in response to CNP could inhibit the export of HA (Fig. 2). In the presence of IL-1β, 
HA production was significantly increased when compared to untreated controls and 
the response was reduced with CNP or the MRP inhibitor MK571 (all p<0.001; Fig. 
2A). The ability of CNP to block the cytokine-induced production of HA was 
diminished in constructs cultured with the Npr2 antagonist P19, resulting in a two-
fold increase in HA when compared to constructs treated with IL-1β alone (p<0.001). 
In the absence of CNP, the Npr3 agonist cANF4-23 abolished HA production in 
cytokine treated constructs, (p<0.001). 
We examined whether dynamic compression could influence HA production in 
constructs treated with IL-1β. In the absence of the cytokine, dynamic compression 
did not influence HA production. In unstrained constructs, the cytokine enhanced HA 
production and the response was reduced with CNP or dynamic compression (both 
p<0.001; Fig. 2B). HA production was reduced further with CNP and/or compression 
(p<0.05), with the magnitude of inhibition similar to constructs treated with the Npr3 
agonist cANF4-23. In contrast, the Npr2 antagonist P19 blocked CNP-induced 
inhibition of HA production resulting in high levels of HA in constructs subjected to 
dynamic compression (p<0.001).  
 
Treatment of constructs with IL-1βCM produced catabolic factors mediated by 
HA: In order to assess whether HA production and its fragments in response to IL-1β 
are catabolic, we generated conditioned medium from constructs treated in the 
presence or absence of IL-1β and/or CNP, and used the conditioned medium to 
stimulate patient matched control constructs. By using this approach, we observed 
upregulation of NO and PGE2 release and MMP activity with constructs cultured with 
IL-1βCM when compared to UTCM (all p<0.001, Fig. 3A, B and C, respectively). The 
presence of CNPCM marginally downregulated IL-1-stimulated NO generation 
(p<0.01; Fig. 3A) and MMP activity (p<0.05; Fig. 3C) but did not significantly 
influence PGE2 production.  
We investigated whether the induction of catabolic mediators by IL-1βCM could 
be due to HA and its fragments by using Pep-1, which binds to HA fragments or by 
targeting CD44 and TLR4 receptor activation with blocking antibodies. The inclusion 
of the HA binding peptide to constructs cultured with IL-1βCM significantly inhibited 
NO and PGE2 release when compared to constructs treated with IL-1β
CM alone (both 
p< 0.001), implicating that Pep-1 prevents the catabolic action of HA (Fig. 3A and B). 
The presence of monoclonal antibodies that blocked activation of CD44 or TLR4 
marginally reduced NO release (both p<0.05) but not PGE2 in IL-1β
CM when 
compared to treatment with the IL-1βCM alone (Fig. 3A and B).  
 MMP activity was enhanced with IL-1βCM but reduced with CNPCM (p<0.05) or 
Pep-1 (p<0.01; Fig. 3C). Anti-CD44 or anti-TLR4 inhibited MMP activity similar to 
controls (both p<0.001; Fig. 3C). GAG synthesis was upregulated with CNPCM when 
compared to UTCM (p<0.001; Fig. 3D). IL-1βCM reduced GAG synthesis (p<0.05) and 
was marginally reversed with constructs treated with IL-1β + CNPCM (p<0.05) or Pep-
1 (p<0.01). Anti-CD44 and anti-TLR4 marginally reversed GAG synthesis when 
compared to constructs treated with IL-1βCM (both p<0.05; Fig. 3D).  
 
Pro-inflammatory cytokine production was reduced by HA inhibitor: Analysis of 
cytokine production by multiplex assay demonstrated up-regulation of TNFα, IL-1β, 
IL-8, IL-10, IL-13 and IFN in IL-1β-treated conditioned media when compared to 
untreated controls (Fig. 4 and Table 1). The presence of Pep-1 significantly reduced 
TNF and IL-1β production (both p<0.001) and the response to the IL-1βCM was 
influenced with blocking antibodies that prevented receptor activation of CD44 and 
TLR4 (Fig. 4). We observed increases for IL-10, IL-13 and IFN-γ levels in constructs 
stimulated with IL-1βCM (all p<0.001, Table 1) but not IL-1, IL-2, IL-5 and IL-12 p70 
(data not shown). In addition, the upregulation of IL-8, IL-10, and IFN-γ by the 
presence of the IL-1βCM was marginally influenced by the interventions tested, 
suggesting that this upregulation may be due to soluble factors related to multiple 
pathways involving HA and other intracellular signalling mechanisms (Table 1).    
 
Discussion  
It is well established that HA fragments will contribute to the pathological process by 
activating catabolic events involving cytokines, MMPs, aggrecanases leading to 
chondrolysis, apoptosis and tissue breakdown [19-20, 29]. However, high molecular 
weight HA was reported to be exported through MRP5 and exerts a protective effect 
via CD44 activation, thereby offering protection in response to the inflammatory 
environment [22, 30-33]. In contrast, HA oligosaccharides found in diseased 
cartilage or synovial joint tissues will promote catabolic signalling via CD44 or TLR4 
[22-24, 30, 32-35]. Since we reported homeostatic effects of the CNP/Npr2/cGMP 
pathway, we hypothesised that cGMP could inhibit HA export function of MRP, 
thereby preventing downstream inflammatory effects induced by HA fragmentation.  
The present study confirmed induction of MRP gene expression and HA 
production in response to IL-1β that was diminished with CNP. Our data is consistent 
with previous studies in chondrocytes and synoviocytes cultured in alginate beads or 
monolayer, which also showed an upregulation of HA production and fragmentation 
in response to IL-1α, IL-1β or TNFα [36-38]. HA oligosaccharides stimulate HA 
synthase 2 (HAS-2), CD44 and aggrecan gene expression leading to proteoglycan 
loss [15, 22]. In the present study, blockade of HA export with the MRP5 inhibitor 
MK571 diminished HA production in response to IL-1β and correlates with previous 
studies in human chondrocytes or bovine cartilage explants [14-15]. Interventions 
designed to mimic the actions of cGMP or interfere with MRP5 export or block HA 
breakdown with inhibitors that affect the action of hyaluronidases was shown to 
reduce proteoglycan and collagen degradation and MMPs in cartilage explants 
treated with IL-1 [16, 17-18]. HA export was inhibited with ODQ which increased 
intracellular levels of cGMP implying that specific HA export inhibitors could be used 
to attenuate matrix loss. Since a number of transport inhibitors are used clinically, 
the efficacy of the HA exporters should be explored to potentially treat matrix 
disorders. In addition, the production of HA in response to IL-1β was reduced with 
CNP and/or mechanical loading or the presence of agents that induce CNP 
signalling (cANF4-23). There is growing evidence that enhanced signalling via the 
CNP/Npr2/cGMP route will induce homeostatic effects in chondrocytes [5-11]. In 
contrast, the Npr2 antagonist P19 had the opposite effect and enhanced HA 
production, confirming that blockade of the CNP/Npr2 signalling system has an 
impact on HA export. The data also complements our previous observations 
demonstrating a protective role for physiological mechanical loading in maintaining 
cartilage homeostasis. In concert with the present findings, the application of cyclic 
tensile strain to synovial fibroblasts influenced the expression and activity of HA 
production and hyaluronidase enzymes [40], emphasising the critical role of 
mechanical loading in maintaining cartilage homeostasis.  
To test whether chemical agents that interfered with HA binding (Pep-1) or 
inhibit HA receptor activation (αCD44 or αTLR4), we generated IL-1βCM in 
anticipation the inflammatory environment promotes the generation of HA 
oligosaccharides that could be blocked by the interventions examined. Culturing 
constructs with IL-1βCM increased production of NO, PGE2 and MMPs that was 
associated with an inhibition of GAG synthesis. We also observed increased 
production of pro-inflammatory (TNF-α, IL-1β, IL-8), anti-inflammatory (IL-10) and 
immunoregulatory cytokines (IFN-γ) that was reduced with CNPCM, implying 
protective effects of CNP against cytokine induction. Few studies have examined the 
effects of CNP on cytokine and immunoregulatory function in chondrocytes.  
The HA binding peptide, Pep-1 diminished cytokine production in response to 
constructs treated with IL-1βCM and this reduction was greater in comparison to 
agents that prevent CD44 and TLR4 receptor activation. Since we did not examine 
the combined effect of the two blocking agents in our conditioned media model, it is 
possible that low molecular weight HA will induce signalling events through both 
receptors. For example, binding of small HA oligosaccharides to CD44 and TLR4 
results in NF-κβ activation, and cytokine production involving TNFα, IL-1β, IL-6 and 
IL-18 [22-23]. Further studies are needed to explore the interactions of the 
CNP/cGMP pathway on HA signalling in chondrocytes.  
The cytokine-treated conditioned media model provides an inflammatory 
environment that could be influenced with interventions that blocked HA binding or 
activation of the HA receptors. The present study suggest that CNP will module the 
pro-inflammatory actions of cytokines and protective effects of the Npr2/cGMP 
signalling pathway should be exploited further.  
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Figure Legends 
 
Fig. 1. Effect of IL-1β and/or CNP on MRP gene expression. Constructs were 
cultured with 0 or 10 ng/ml IL-1β and/or 100 nM CNP for 6 hours. Error bars 
represent the mean and SEM values of 6 replicates from two separate experiments. 
(*,** or ***) indicates significant comparisons for the multiple treatment conditions.  
 
Fig. 2. Effect of free-swelling culture and/or dynamic compression on HA 
production. Constructs were cultured  with 0 or 10 ng/ml IL-1β and/or 100 nM CNP 
or 0.5 µM MK571 or 0.5 µM P19 or 1 µM cANF4-23 for 48 hours (A). In separate 
experiments, constructs were subjected to dynamic compression (15%, 1Hz) for 48 
hours under similar treatments (B). Error bars represent the mean and SEM values 
of between 12 and 18 replicates from six separate experiments. (*,** or ***) indicates 
significant comparisons for the multiple treatment conditions.  
 
Fig. 3. Effect of conditioned media and HA pharmacological agents on 
catabolic activities. Constructs were cultured with conditioned media for IL-1β (IL-
1CM), CNP (CNPCM) or both (IL-1β + CNPCM) and treated with inhibitors for HA 
signalling (Pep-1, αCD44 or αTLR4 blocking antibodies) for a further 48 hours, on 
NO release (A), PGE2 release (B), Total MMP activity (C) and GAG synthesis (D). 
Error bars represent the mean and SEM values of between 8 and 10 replicates from 
3-4 separate experiments. (*,** or ***) indicates significant comparisons for the 
multiple treatment conditions.  
 
Fig. 4. Effect of conditioned media and HA pharmacological agents on pro-
inflammatory cytokine production. Constructs were cultured with conditioned 
media for IL-1β (IL-1CM), CNP (CNPCM) or both (IL-1β + CNPCM) and treated with 
inhibitors for HA signalling (Pep-1, αCD44 or αTLR4 blocking antibodies) for a further 
48 hours, on TNF (A) and IL-1 production (B) Error bars represent the mean and 
SEM values of 10 replicates from 4 separate experiments. (*,** or ***) indicates 
significant comparisons for the multiple treatment conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: The effect of HA inhibitors on cytokine production in constructs cultured 
with IL-1 and/or CNP conditioned media 
 UT vs 
CNPCM 
UT vs IL-
1CM 
IL-1CM vs  
IL-1 + 
CNPCM 
IL-1CM 
vs  
IL-1CM + 
Pep-1 
IL-1CM vs  
IL-1CM + 
CD44 
IL-1CM vs  
IL-1CM + 
TLR4 
TNF
 
5.9 
(9.5) 
187.1 
(23.9) 
-48.5 
(6.3) 
-63.8 
(6.1) 
-36.7 
(7.4) 
-35.4 
(7.0) 
IL-1
 
8.3 
(13.5) 
5362.9 
(508.2) 
-16.6 
(22.6) 
-59.4 
(28.5) 
-10.2 
(8.4) 
-11.0 
(8.2) 
IL-8 
 
12.4 
(10.6) 
95.9 
(6.0) 
-4.5 
(4.5) 
8.2 
(4.2) 
10.6 
(5.4) 
-10.8 
(3.9) 
IL-10 
 
32.6 
(16.0) 
737.8 
(79.0) 
-53.7 
(13.0) 
-25.1 
(23.6) 
-7.9 
(27.4) 
-9.9 
(25.4) 
IL-13 
 
-3.1 
(1.4) 
39.2 
(2.8) 
-14.5 
(4.9) 
-10.6 
(6.1) 
-17.2 
(2.6) 
3.7 
(6.2) 
IFN-γ 
 
17.3 
(2.6) 
237.3 
(24.3) 
-2.1 
 (8.5) 
-1.4 
(5.6) 
-4.3 
(6.1) 
7.5 
(4.8) 
 
Note: Constructs were cultured with conditioned media for IL-1β (IL-1CM), CNP (CNPCM) or 
both (IL-1β + CNPCM) and treated with agents that blocked HA binding (Pep-1) or HA 
receptor activation (αCD44 or αTLR4) for a further 48 hours. The production of pro-
inflammatory (TNFα, IL-1β and IL-8), anti-inflammatory (IL-10, IL-13) and immunoregulatory 
(IFN-) cytokines were examined. All values are expressed as a percentage difference (%) 
for the comparisons stated, where SEM was calculated for n=8-10 constructs from 3-4 
separate experiments.  
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